Black phosphorus nanoparticles for dual therapy of non-small cell lung cancer
Authors:
- 2 February 2022
- journal article
- research article
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 30 (6) , 614-622
Abstract
Lung cancer remains one of the leading causes of death in humans. Gefitinib is an inhibitor of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) commonly used to suppress tumour growth. However, constantly use of gefitinib results in drug-resistance, reduced efficacy and undesired side effects. To circumvent these drawbacks, targeted and photothermal therapies have emerged as effective strategies. Herein, we are first to adopt a black phosphorus (BP) nanoparticle-based novel delivering strategy by combining gefitinib and cancer cytomembrane to treat non-small cell lung cancer (NSCLC). In these gefitinib-containing nano-carriers, cyanine 5 (Cy5) biotin-labelled BP was incorporated with cancer membrane and then consists of a nanomaterial (BPGM), which enabled to deliver gefitinib to the tumours effectively. The combination of BPGM showed reinforcing effects to suppress NSCLC cells and xenograft tumours without apparent adverse effects both in vitro and in vivo. BPGM facilitated the delivery of gefitinib to tumour tissue and extended its retention time within tumours. These studies thus suggest that BP may serve as novel delivery strategy for lung cancer.Keywords
Funding Information
- National Natural Science Foundation of China
- Bureau of Education of Guangzhou Municipality
- Guangdong Provincial Department of Science and Technology
This publication has 38 references indexed in Scilit:
- Cell membrane-camouflaged nanoparticles for drug deliveryJournal of Controlled Release, 2015
- Ultrasmall Black Phosphorus Quantum Dots: Synthesis and Use as Photothermal AgentsAngewandte Chemie International Edition, 2015
- First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE studyAnnals of Oncology, 2015
- PLGA-Based Nanoparticles as Cancer Drug Delivery SystemsAsian Pacific Journal of Cancer Prevention, 2014
- Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLCCancer Discovery, 2013
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapyLung Cancer, 2012
- PCN72 COST-UTILITY ANALYSIS OF GEFITINIB VERSUS DOCETAXEL IN A MEXICAN PUBLIC INSTITUTIONValue in Health, 2009
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATPProceedings of the National Academy of Sciences, 2008
- Gefitinib: an adverse effects profileExpert Opinion on Drug Safety, 2006